ブランドジェネリックの世界市場レポート 2025

ブランドジェネリック市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.9％で6,014億米ドルに成長します。予測期間の成長は、ジェネリック生物製剤の需要拡大、慢性疾患の増加、新興市場の成長、バイオシミラーへの注目などに起因すると考えられます。予測期間の主な動向には、戦略的提携や共同研究、技術の進歩、慢性疾患への注力、市場統合、患者中心のアプローチなどがあります。

慢性疾患の急増がブランドジェネリック市場の拡大に拍車をかけると予想されます。タバコの使用、食生活の乱れ、座りっぱなしのライフスタイル、過度のアルコール摂取などの要因により、多くの場合不治の病ではあるが管理可能なこれらの不治の病は増加傾向にあります。慢性疾患の治療には、標準的な薬に比べ費用対効果が高いブランドジェネリックが好まれる傾向が世界的に強まっています。この動向を浮き彫りにするように、2022年9月、世界保健機関（WHO）は世界で4,100万人が死亡しており、これは年間非感染性疾患（NCD）死亡者数の74％に相当すると報告しました。このような慢性疾患の増加は、近い将来、ブランドジェネリックの需要を高めることになるでしょう。

製薬業界におけるニーズの高まりが、ブランドジェネリック市場の上昇を後押ししています。医療用医薬品の研究開発、生産、マーケティングを専門とするこの業界では、先発医薬品に代わる経済的な選択肢としてブランドジェネリックが注目されています。さらに、これらのジェネリック医薬品は、製剤がジェネリック医薬品として入手可能な場合でも、慣れ親しんだ信頼できる製品を提供することで、患者の忠誠心を維持するのに役立っています。特に、2023年6月の欧州製薬団体連合会（EFPIA）によると、2022年の欧州の医薬品生産額は3,842億米ドル（3,400億ユーロ）に達し、前年比4.95％増となりました。この医薬品需要の急増がブランドジェネリック市場の成長を支えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ブランドジェネリック PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のブランドジェネリック市場：成長率分析
• 世界のブランドジェネリック市場の実績：規模と成長, 2019-2024
• 世界のブランドジェネリック市場の予測：規模と成長, 2024-2029, 2034F
• 世界ブランドジェネリック総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のブランドジェネリック市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルキル化剤
• 代謝拮抗物質
• ホルモン
• 降圧剤
• 脂質低下薬
• 抗うつ薬
• 抗精神病薬
• 抗てんかん薬
• その他の薬物
• 世界のブランドジェネリック市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 話題
• オーラル
• 非経口
• その他の投与経路
• 世界のブランドジェネリック市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 心血管疾患
• 糖尿病
• 神経学
• 消化器疾患
• 皮膚科疾患
• 鎮痛剤と抗炎症剤
• その他の用途
• 世界のブランドジェネリック市場アルキル化剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 窒素マスタード
• エチレンイミン化合物
• 世界のブランドジェネリック市場代謝拮抗剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プリン類似体
• ピリミジン類似体
• 世界のブランドジェネリック市場ホルモンの種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 甲状腺ホルモン
• 世界のブランドジェネリック市場、降圧剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ACE阻害薬
• ベータ遮断薬
• カルシウムチャネル遮断薬
• 世界のブランドジェネリック市場脂質低下薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ACE阻害薬
• ベータ遮断薬
• カルシウムチャネル遮断薬
• 世界のブランドジェネリック市場抗うつ薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• SSRI（選択的セロトニン再取り込み阻害薬）
• SNRI（セロトニン・ノルエピネフリン再取り込み阻害剤）
• 世界のブランドジェネリック市場、抗精神病薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非定型抗精神病薬
• 典型的な抗精神病薬
• 世界のブランドジェネリック市場抗てんかん薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナトリウムチャネル遮断薬
• GABA作動薬
• 世界のブランドジェネリック市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鎮痛剤
• 抗生物質
• 抗ウイルス薬

第7章 地域別・国別分析

• 世界のブランドジェネリック市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のブランドジェネリック市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ブランドジェネリック市場：競合情勢
• ブランドジェネリック市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Alkem Laboratories Ltd.
• Mylan N.V.
• Sandoz International GmbH
• Bausch Health Companies Inc.
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.
• Apotex Inc.
• Aspen Pharmacare Holdings Limited
• Endo International plc
• Towa Pharmaceutical Co. Ltd.
• Mankind Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ブランドジェネリック市場2029：新たな機会を提供する国
• ブランドジェネリック市場2029：新たな機会を提供するセグメント
• ブランドジェネリック市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Branded generics denote unregistered medications marketed under a specific brand name, offering distinct advantages to patients and healthcare providers, fostering brand preference. They encompass generic drugs distinguished by a unique brand identity and may be promoted akin to branded medications.

Branded generics encompass several drug classes, such as alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid-lowering drugs, anti-depressants, anti-psychotics, anti-epileptics, and others. Alkylating agents within branded generics are a subset of anticancer medications that impede DNA-to-RNA conversion, effectively disrupting protein synthesis. These chemicals modify hydrogen atoms on DNA to alkyl groups, inducing cross-links within the DNA strand, leading to cytotoxic, mutagenic, and carcinogenic effects. Branded generics offer various administration routes including topical, oral, parenteral, and others. They cater to diverse medical conditions encompassing oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal ailments, dermatological conditions, analgesics, anti-inflammatory treatments, and more.

The branded generics market research report is one of a series of new reports from The Business Research Company that provides branded generics market statistics, including branded generics industry global market size, regional shares, competitors with a branded generics market share, detailed branded generics market segments, market trends and opportunities, and any further data you may need to thrive in the branded generics industry. This branded generic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The branded generics market size has grown strongly in recent years. It will grow from $363.49 billion in 2024 to $397.19 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to cost savings and affordability, patent expiries, market expansion and access, government initiatives and policies, healthcare reforms.

The branded generics market size is expected to see rapid growth in the next few years. It will grow to $601.4 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to growing demand for generic biologics, rising chronic diseases, emerging markets growth, focus on biosimilars. Major trends in the forecast period include strategic partnerships and collaborations, technological advancements, focus on chronic diseases, market consolidation, patient-centric approach.

The burgeoning prevalence of chronic diseases is anticipated to fuel the expansion of the branded generics market. These enduring ailments, often incurable but manageable, are on the rise due to factors such as tobacco use, poor dietary habits, sedentary lifestyles, and excessive alcohol consumption. The global populace increasingly favors branded generics for treating chronic conditions, attracted by their cost-effectiveness compared to standard medications. Highlighting this trend, in September 2022, the World Health Organization (WHO) reported 41 million deaths worldwide, representing 74% of all noncommunicable disease (NCD) fatalities annually. This upsurge in chronic diseases is poised to elevate the demand for branded generics in the foreseeable future.

The escalating need within the pharmaceutical sector is set to propel the ascent of the branded generics market. This industry, dedicated to drug research, development, production, and marketing for medical purposes, leans on branded generics as an economical alternative to branded drugs. Additionally, these generics help sustain patient loyalty by offering a familiar, trusted product, even when the formulation is available as a generic. Notably, as per the European Federation of Pharmaceutical Industries and Associations (EFPIA) in June 2023, the pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from the previous year. This surge in pharmaceutical demand underpins the growth of the branded generics market.

Strategic partnerships are a significant trend in the branded generics market, with companies collaborating to leverage each other's resources and expand into new markets. For example, in September 2024, Biocon Ltd., an India-based pharmaceutical company, formed a partnership with Tabuk Pharmaceuticals. Under this agreement, Biocon will develop and manufacture GLP-1 products, ensuring the delivery of high-quality biopharmaceuticals for diabetes treatment. Tabuk Pharmaceuticals will manage the marketing authorization rights, handling the registration, importation, and promotion of these products across the Middle East, particularly in Saudi Arabia. The partnership also includes plans for future expansion into additional GLP products, broadening the range of diabetes treatments available. This collaboration aims to provide unique health solutions that enhance patient well-being in Saudi Arabia and surrounding regions, reflecting both companies' commitment to improving healthcare access. Tabuk Pharmaceuticals, based in Saudi Arabia, markets both branded and generic pharmaceutical products.

In June 2022, Dr. Reddy's Laboratories, a prominent Indian pharmaceutical firm specializing in branded generics, completed the acquisition of branded and generic injectable products from Eton Pharmaceuticals, Inc., a US-based pharmaceutical company. This transaction, valued at $50 million, serves Dr. Reddy's Laboratories' strategic agenda to expedite and broaden the availability of affordable medications. The acquisition includes notable products such as Biorphen (phenylephrine hydrochloride) injection and Rezipres, augmenting their efforts to introduce biosimilars into the market.

In May 2023, Yaral Pharma, a Switzerland-based pharmaceutical company, partnered with Eversana Life Science Services LLC. This collaboration aims to enhance Yaral Pharma's portfolio of pain and endocrinology products in the US market. By working with Eversana, Yaral Pharma seeks comprehensive commercialization services, including logistics and operational support. Eversana Life Science Services LLC is a US-based company that specializes in providing extensive commercialization and consulting services for the life sciences industry.

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the branded generics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The branded generics market consists of sales of glucophage, lopressor, and trimox. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Branded Generics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on branded generics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for branded generics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The branded generics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Alkylating Agents; Antimetabolites; Hormones; Anti-Hypertensive; Lipid Lowering Drugs; Anti-Depressants; Anti-Psychotics; Anti-Epileptics; Other Drugs
• 2) By Route Of Administration: Topical; Oral; Parenteral; Other Routes Of Administration
• 3) By Application: Oncology; Cardiovascular Diseases; Diabetes; Neurology; Gastrointestinal Diseases; Dermatology Diseases; Analgesics And Anti-inflammatory; Other Applications
• Subsegments:
• 1) By Alkylating Agents: Nitrogen Mustards; Ethylene Imine Compounds
• 2) By Antimetabolites: Purine Analogues; Pyrimidine Analogues
• 3) By Hormones: Corticosteroids; Thyroid Hormones
• 4) By Anti-Hypertensive: ACE Inhibitors; Beta Blockers; Calcium Channel Blockers
• 5) By Lipid Lowering Drugs: Statins; Fibrates
• 6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors); SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
• 7) By Anti-Psychotics: Atypical Antipsychotics; Typical Antipsychotics
• 8) By Anti-Epileptics: Sodium Channel Blockers; GABAergic Drugs
• 9) By Other Drugs: Analgesics; Antibiotics; Antivirals
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Sanofi SA; AstraZeneca plc; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Branded Generics Market Characteristics

3. Branded Generics Market Trends And Strategies

4. Branded Generics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Branded Generics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Branded Generics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Branded Generics Market Growth Rate Analysis
• 5.4. Global Branded Generics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Branded Generics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Branded Generics Total Addressable Market (TAM)

6. Branded Generics Market Segmentation

• 6.1. Global Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptics
• Other Drugs
• 6.2. Global Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical
• Oral
• Parenteral
• Other Routes Of Administration
• 6.3. Global Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Cardiovascular Diseases
• Diabetes
• Neurology
• Gastrointestinal Diseases
• Dermatology Diseases
• Analgesics And Anti-inflammatory
• Other Applications
• 6.4. Global Branded Generics Market, Sub-Segmentation Of Alkylating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrogen Mustards
• Ethylene Imine Compounds
• 6.5. Global Branded Generics Market, Sub-Segmentation Of Antimetabolites, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Purine Analogues
• Pyrimidine Analogues
• 6.6. Global Branded Generics Market, Sub-Segmentation Of Hormones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Thyroid Hormones
• 6.7. Global Branded Generics Market, Sub-Segmentation Of Anti-Hypertensive, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• ACE Inhibitors
• Beta Blockers
• Calcium Channel Blockers
• 6.8. Global Branded Generics Market, Sub-Segmentation Of Lipid Lowering Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• ACE Inhibitors
• Beta Blockers
• Calcium Channel Blockers
• 6.9. Global Branded Generics Market, Sub-Segmentation Of Anti-Depressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SSRIs (Selective Serotonin Reuptake Inhibitors)
• SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
• 6.10. Global Branded Generics Market, Sub-Segmentation Of Anti-Psychotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.11. Global Branded Generics Market, Sub-Segmentation Of Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sodium Channel Blockers
• GABAergic Drugs
• 6.12. Global Branded Generics Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Antibiotics
• Antivirals

7. Branded Generics Market Regional And Country Analysis

• 7.1. Global Branded Generics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Branded Generics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Branded Generics Market

• 8.1. Asia-Pacific Branded Generics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Branded Generics Market

• 9.1. China Branded Generics Market Overview
• 9.2. China Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Branded Generics Market

• 10.1. India Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Branded Generics Market

• 11.1. Japan Branded Generics Market Overview
• 11.2. Japan Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Branded Generics Market

• 12.1. Australia Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Branded Generics Market

• 13.1. Indonesia Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Branded Generics Market

• 14.1. South Korea Branded Generics Market Overview
• 14.2. South Korea Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Branded Generics Market

• 15.1. Western Europe Branded Generics Market Overview
• 15.2. Western Europe Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Branded Generics Market

• 16.1. UK Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Branded Generics Market

• 17.1. Germany Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Branded Generics Market

• 18.1. France Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Branded Generics Market

• 19.1. Italy Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Branded Generics Market

• 20.1. Spain Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Branded Generics Market

• 21.1. Eastern Europe Branded Generics Market Overview
• 21.2. Eastern Europe Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Branded Generics Market

• 22.1. Russia Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Branded Generics Market

• 23.1. North America Branded Generics Market Overview
• 23.2. North America Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Branded Generics Market

• 24.1. USA Branded Generics Market Overview
• 24.2. USA Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Branded Generics Market

• 25.1. Canada Branded Generics Market Overview
• 25.2. Canada Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Branded Generics Market

• 26.1. South America Branded Generics Market Overview
• 26.2. South America Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Branded Generics Market

• 27.1. Brazil Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Branded Generics Market

• 28.1. Middle East Branded Generics Market Overview
• 28.2. Middle East Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Branded Generics Market

• 29.1. Africa Branded Generics Market Overview
• 29.2. Africa Branded Generics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Branded Generics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Branded Generics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Branded Generics Market Competitive Landscape And Company Profiles

• 30.1. Branded Generics Market Competitive Landscape
• 30.2. Branded Generics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Branded Generics Market Other Major And Innovative Companies

• 31.1. Viatris Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Alkem Laboratories Ltd.
• 31.4. Mylan N.V.
• 31.5. Sandoz International GmbH
• 31.6. Bausch Health Companies Inc.
• 31.7. Sun Pharmaceutical Industries Ltd.
• 31.8. Cipla Ltd.
• 31.9. Aurobindo Pharma Ltd.
• 31.10. Dr. Reddy's Laboratories Ltd.
• 31.11. Apotex Inc.
• 31.12. Aspen Pharmacare Holdings Limited
• 31.13. Endo International plc
• 31.14. Towa Pharmaceutical Co. Ltd.
• 31.15. Mankind Pharma

32. Global Branded Generics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Branded Generics Market

34. Recent Developments In The Branded Generics Market

35. Branded Generics Market High Potential Countries, Segments and Strategies

• 35.1 Branded Generics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Branded Generics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Branded Generics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer